Related Experiment Video
Updated: May 3, 2026

A High-Throughput Multiplexed Screening for Type 1 Diabetes, Celiac Diseases, and COVID-19
Published on: July 5, 2022
Improved screening for cystic fibrosis-related diabetes by an integrated care team using an algorithm
Maria Socorro Rayas1, Donna Beth Willey-Courand, Jane Lockwood Lynch
1Division of Pediatric Endocrinology and Diabetes, University of Texas Health Science Center in San Antonio, San Antonio, Texas.
Insights
A new algorithm improved cystic fibrosis-related diabetes (CFRD) screening compliance initially. However, this improvement was not sustained long-term, highlighting the need to address patient barriers.
Area of Science:
- Pediatric Endocrinology
- Pulmonology
- Quality Improvement Science
Background:
- Cystic fibrosis-related diabetes (CFRD) screening is crucial for early detection and management.
- Current screening guidelines adherence can be variable in clinical practice.
Purpose of the Study:
- To evaluate the effectiveness of a standardized, clinic-based algorithm in improving compliance with CFRD screening guidelines.
- To assess the impact of the algorithm on oral glucose tolerance test (OGTT) completion rates in pediatric CF patients.
Main Methods:
- A quality improvement initiative developed and implemented a prospective CFRD screening algorithm for children aged 8-17 years over 6 months.
- The primary outcome was the rate of appropriately screened patients (OGTT completion) during the intervention period compared to the prior year.
Main Results:
- Algorithm implementation significantly increased OGTT completion rates (P=0.03) during the initial 6-month period.
- While provider ordering compliance remained high (97%), patient completion rates decreased in the year following implementation (79%), showing no significant improvement over baseline (P=0.08).
Conclusions:
- A standardized algorithm initially improved CFRD screening compliance.
- The positive impact on patient screening was not sustained long-term, indicating potential barriers to patient adherence that require further investigation.
Objective:
To determine whether implementation of a standardized, clinic-based algorithm improves compliance with cystic fibrosis-related diabetes (CFRD) screening guidelines.
Study Design:
A CFRD screening algorithm was developed as part of a quality improvement initiative through collaboration between the pediatric pulmonary and endocrine divisions and implemented prospectively to children aged 8-17 years in our CF center for a 6-month period. The primary outcome measure was the percentage rate of CF patients who were appropriately screened with an oral glucose tolerance test (OGTT) during the quality improvement period as compared to the year prior.
Results:
Ninety-seven percent (37/38) of OGTTs were appropriately ordered by providers, and 89% (34/38) of patients obtained the OGTT at the completion of the quality improvement period. Compared with the percentage of eligible patients completing the OGTT the year prior, the use of the algorithm significantly improved screening (P = 0.03). Data collected 1-year post-algorithm implementation revealed 97% (33/34) of OGTTs were ordered and 79% (27/34) of OGTTs were completed. The use of the algorithm 1-year post-implementation did not reveal a significant improvement in screening when compared to the reference year and implementation period (P = 0.08).
Conclusions:
Implementation of a clinical algorithm resulted in a statistically significant improvement in screening during the quality improvement period, but this improvement was not sustained the following year despite continued physician compliance with ordering the OGTT. Barriers to patient compliance need to be explored.
Related Concept Videos
Chronic Pancreatitis II: Collaborative Care
Assessment:
Cystic Fibrosis: Management
Sinus disease and chronic...
Methods of Documentation VI: Case Management Model
For example, a patient with a chronic...
Type II Diabetes Mellitus III: Clinical Manifestations and Diagnosis
Diabetes: Management and Pharmacotherapy
Insulin remains the cornerstone of treatment for most patients with type 1 and many...

